INVESTOR

Reminder: Invitation to Roche’s First Quarter Sales 2026 Presentation

Thu, 16 Apr 2026 08:00:00 GMT

Roche will publish its Sales Results for the 1^st Quarter 2026 prior to the opening of the Swiss Stock Exchange on Thursday, 23 April 2026. 07:00 CEST / 06:00 BST / 01:00 AM EDT / 10:00 PM PDT (evening before) Release will be e-mailed and posted on the Roche IR website > click here Presentation slides will be posted on the Roche IR website > click here 14:00 – 15:30 CEST / 13:00 – 14:30 BST 08:00 – 09:30 AM EDT / 05:00 - 06:30 AM PDT The webinar will start with presentations by senior management, followed by a Q&A session. Presenters: Thomas Schinecker, CEO Roche Group Alan Hippe, Chief Financial Officer Teresa Graham, CEO Roche Pharmaceuticals Matt Sause, CEO Roche Diagnostics We would like to invite all interested parties to participate in the webinar and to pre-register for the event here.* Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice Best regards,
Bruno Eschli Head of Investor Relations
Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform

Thu, 16 Apr 2026 11:00:00 GMT

Pathlight™, a personalized, tumor-informed molecular residual disease (MRD) platform, will expand Foundation Medicine’s testing capabilities
Pathlight uses a proprietary combination of whole genome sequencing (WGS) and digital PCR to identify and track structural variants (SVs) enabling ultra-sensitive MRD detection

Boston,16 April 2026 - Foundation Medicine, Inc., a global, patient-focused precision medicine company and an independent affiliate of the Roche group (SIX: RO, ROP; OTCQX: RHHBY) announced it is set to expand its monitoring portfolio with SAGA Diagnostics’ tumor-informed molecular residual disease (MRD) platform as a result of Roche entering into a definitive merger agreement to acquire SAGA. Roche will pay a total of up to $595 million, inclusive of commercial and regulatory milestone payments. The transaction is subject to customary closing conditions including regulatory approvals, and is expected to close in Q3 2026, at the latest. Following the closing of the transaction, the platform will be fully integrated into Foundation Medicine.

Pathlight’s MRD platform will strengthen Foundation Medicine’s portfolio of high-quality diagnostic tests and solutions that support treatment selection, and the monitoring of both treatment response and disease recurrence. Foundation Medicine also plans to leverage Roche’s AXELIOS sequencing platform¹ and the Digital LightCycler® PCR platform to develop a decentralized MRD solution which will enable patient access in healthcare settings worldwide.

Pathlight uses a proprietary combination of whole genome sequencing (WGS) and digital PCR to identify and track large-scale genomic changes known as structural variants (SVs). By optimizing for SVs, Pathlight enables ultra-sensitive MRD detection. Pathlight is covered by Medicare for cancer recurrence monitoring in early-stage breast cancer across all subtypes. It is currently available for patients within the United States², with plans for international launch.

“Pathlight strengthens our comprehensive portfolio of diagnostic solutions and reinforces our commitment to transforming cancer care throughout a patient’s experience,” said Dan Malarek, CEO of Foundation Medicine. “MRD is one of the fastest-growing areas within diagnostics and this technology provides us with a clinically available ultra-sensitive offering. Pathlight has demonstrated strong clinical performance in breast and colorectal cancer, and we look forward to expanding its applicability across other tumor types and indications to improve the lives of even more patients.”

“Our mission at SAGA is to intercept cancer early when patients are most treatable and curable," said Roopom Banerjee, Executive Chairman of SAGA. “Foundation Medicine’s commercial scale and innovation accelerates our ability to bring this unique MRD platform to more patients worldwide. We are proud of our team for advancing innovation in the MRD field and commercially launching Pathlight to improve patient outcomes.”

Pathlight will expand Foundation Medicine’s monitoring portfolio, which includes FoundationOne®Monitor³ and Foundation Medicine’s tissue-informed whole genome sequencing molecular residual disease test (Tissue-Informed WGS MRD) available for research use⁴^. FoundationOne Monitor is a circulating tumor DNA (ctDNA) monitoring test which uses a blood sample to support healthcare providers with clarity on their patient’s response to treatment and inform next steps in care. The Tissue-Informed WGS MRD test monitors hundreds to thousands of tumor-specific short variants, enabling accurate quantification of ctDNA in patients with cancer for a more complete picture after treatment.

Foundation Medicine and FoundationOne are registered trademarks of Foundation Medicine, Inc.

SAGA Diagnostics is a registered trademark and Pathlight is a trademark of SAGA Diagnostics.

About Foundation Medicine
Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. We provide tests and solutions to transform care throughout a patient’s experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools, expanding the information our diagnostic solutions provide to enable improved outcomes for patients. Every day, we are inspired to think differently to transform the lives of people living with cancer and other diseases. For more information, visit us at www.FoundationMedicine.com and follow us on LinkedIn, X, YouTube, Facebook, Instagram and BlueSky.

About FoundationOne®Monitor
FoundationOne®Monitor is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. This test has not been cleared or approved by the U.S. Food and Drug Administration. FoundationOne Monitor is a test for patients with solid malignant neoplasms that detects and longitudinally tracks circulating tumor DNA (ctDNA), reported as ctDNA tumor fraction (a determination of the amount of ctDNA as a fraction of total cell free DNA in a blood sample) as a biomarker for tumor content in the blood. Treatment decisions are the responsibility of the treating physician. ctDNA tumor fraction determination sensitivity may be limited if blood collection occurs within two weeks of surgery. ctDNA not detected status does not definitively indicate the absence of cancer and declining ctDNA tumor fraction does not necessarily indicate a response to therapy. This test is not designed to detect or report germline variation, nor does it infer hereditary cancer risk for a patient. This test is expected to have limited sensitivity in some cancer types due to limited ctDNA shed.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] AXELIOS sequencing platform is in development and not commercially available.
[2] Not approved by New York State.
[3] FoundationOne®Monitor is a laboratory developed test which has not been reviewed or approved by the FDA.
[4] Tissue-Informed WGS MRD is For Research Use Only. Not for use in diagnostic procedures.

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Attachment

260416_IR_Release_FMI_EN

Reminder: Invitation to Roche’s Virtual AAN Investor Event

Wed, 15 Apr 2026 08:00:00 GMT

We are pleased to invite investors and analysts to participate in our virtual event on Wednesday, 22 April 2026, to highlight the new data from the Phase III FENhance1/2 study evaluating fenebrutinib vs. Aubagio in RMS, which will be presented at the American Academy of Neurology (AAN) forum from 18-22 April 2026.

17:00-18:00 CEST / 16:00-17:00 BST
8:00-9:00 PDT / 11:00-12:00 EDT

Agenda
Introduction
Bruno Eschli, Head of Investor Relations

Fenebrutinib development overview
Alexandra Goodyear, Lifecycle Leader Fenebrutinib

Ph III (FENhance 1/2) fenebrutinib vs. Aubagio in RMS
Jiwon Oh, MD, PhD, FRCPC, Medical Director, Barlo Multiple Sclerosis Program, Associate Professor, Division of Neurology, St. Michael’s Hospital, University of Toronto, Staff Neurologist, St. Michael’s Hospital, Scientist, Keenan Research Centre of the Li Ka Shing Knowledge Institute

Q&A

The slides will be available for download at 16:00 CEST on the day of the event. > click here

Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli Head of Investor Relations	Loren Kalm Head of Investor Relations, North America
Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Reminder: Invitation to Roche’s Diagnostics Day 2026

Tue, 14 Apr 2026 12:00:00 GMT

The Roche Investor Relations team would like to invite you to the Roche Diagnostics Day taking place in London on Tuesday, 12 May 2026, starting at 12:00 BST local time and finishing at 16:20 BST, followed by refreshments with the Roche Management Team.

The Roche Diagnostics Day will address the following topics:

Group and Diagnostics division strategy updates
Launch updates for mass spectrometry, SBX sequencing, and CGM
Foundation Medicine strategy and highlights
Portfolio updates on Core Lab, Molecular Lab, Near Patient Care, and Pathology Lab

Presenters include:

Thomas Schinecker, CEO Roche Group
Matt Sause, CEO Roche Diagnostics
Palani Kumaresan, Global Head of Roche Diagnostics Solutions
Moritz Hartmann, Global Head of Roche Information Solutions
Josh Lauer, Global Head of Customer Area Molecular Labs
Daniel Malarek, CEO Foundation Medicine
Laura Apitz, Head of Pathology Lab Customer Segment
Ildiko Amann-Zalan, Head of Research & Development Roche Diagnostics Solutions
Olivier Gillieron, Lifecycle Leader Cardiometabolic and Neurology

Meeting information:
Date/Time (BST):
Tuesday, 12 May 2026
12:00 – 13:00 Registration and lunch
13:00 – 16:20 Presentations & Q&A
16:20 – 17:00 Refreshments with Roche Management Team

Venue
Pan Pacific London
80 Houndsditch
London EC3A 7AB
> map

To register for the event, please follow this > link (passcode: Dia2026).

The slides will be available for download at 11:30 BST on the day of the event.
> click here

Alternatively you may participate virtually in the webinar (no access to speakers, pre-registration required). Please pre-register for the webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the event will be available via > roche.com/investors

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Birgit Masjost
Investor Relations Officer/Lead Diagnostics

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Mon, 13 Apr 2026 05:00:00 GMT

The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.¹
This minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods.
By providing deeper insight into underlying neuroinflammatory activity, Elecsys NfL has the potential to enable effective MS monitoring and earlier clinical intervention. ^{2, 3}

Basel, 13 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys® Neurofilament Light Chain (NfL) test has received CE mark approval for the detection of neuroinflammation in patients diagnosed with relapsing remitting multiple sclerosis (RRMS).¹ The test brings meaningful innovation to MS disease management, offering clinicians a minimally invasive way to monitor the biological damage caused by multiple sclerosis. Using a simple blood test to measure NfL – a protein released during nerve cell injury – Elecsys NfL provides a picture of the neuroinflammation associated with multiple sclerosis, and could help to make more regular monitoring a reality for more people living with the disease.

Multiple sclerosis is a chronic disease that affects more than 2.9 million people worldwide.⁸ Early and regular monitoring of disease activity is critical to optimising treatment, yet some patients can find it difficult to access routine assessments such as MRI scanning that would allow timely detection of changes in their condition. The Elecsys NfL test provides a different type of insight by measuring biological markers of neuroaxonal damage that reflect neuroinflammation. These insights complement routine clinical assessments and MRI, potentially aiding in earlier and better-informed clinical management.

“This approval marks a transformative step forward in how we support adults with relapsing-remitting multiple sclerosis (RRMS),” said Matt Sause, CEO of Roche Diagnostics. “The availability of a simple blood-based test has the potential to complement resource-intensive MRI scans and improve access for patients with RRMS. The Elecsys NfL test will help healthcare providers support timely clinical reassessment, enabling better disease management and more personalised care for patients.”

Performed on Roche’s widely available cobas instruments, the Elecsys NfL test provides standardised and consistent results,¹ ensuring reliable insights regardless of where the test is carried out. Requiring only a simple blood sample, collections can be done locally, reducing the need for patients to travel to specialist centres. With traditional testing for multiple sclerosis often limited by geographic, financial, or logistical barriers, Elecsys NfL makes frequent monitoring more practical and accessible.

About NfL
Neurofilament Light Chain (NfL) is an abundant cytoskeletal protein⁴ found almost exclusively in neurons⁵ and is a sensitive indicator of neuroaxonal damage^2,6. Under normal conditions, NfL is released at low levels from axons⁴; however, release increases with age⁷ and following neuroaxonal damage.⁴ Consequently, abnormally elevated NfL concentrations can be measured in cerebrospinal fluid and blood in a range of acute and chronic neurological disorders.^{2, 4, 6}

About Elecsys® NfL
Roche’s Elecsys NfL is an in vitro quantitative immunoassay for the measurement of NfL protein in human serum and plasma. Elecsys NfL is intended to be used to reflect neuroinflammation in adult subjects diagnosed with relapsing-remitting multiple sclerosis.²

The test was granted Breakthrough Device Designation by the US FDA in November 2023. Following CE Mark approval, broad access to testing will exist through the large number of instruments currently available in countries accepting CE mark.

About Roche in neurology
Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases globally.

Roche is investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics has developed a broad range of approved and investigational tools, including digital and blood-based tests and Cerebrospinal Fluid (CSF) assays, aiming to more effectively detect, diagnose and monitor neurological conditions.

Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Roche Diagnostics GmbH. Elecsys NfL. Method Sheet 09880488500 V1.0. Roche Diagnostics GmbH; 2025.
[2] Khalil M, et al. Nat Rev Neurol 2018;14:577–89. https://doi.org/10.1038/s41582-018-0058-z
[3] Bar-Or A, et al. EBioMedicine 2023;93:104662. https://doi.org/10.1016/j.ebiom.2023.104662
[4] Gaetani L, et al. J Neurol Neurosurg Psychiatry 2019;90:870–81. https://doi.org/10.1136/jnnp-2018-320106
[5] Gafson AR, et al. Brain 2020;143:1975–98. https://doi.org/10.1093/brain/awaa098
[6] Freedman MS, et al. EBioMedicine 2024;101:104970. https://doi.org/10.1016/j.ebiom.2024.104970
[7] Itorralba J, Schneider R. Pract Neurol (US) 2024;23(2):18–21. https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/the-prognostic-utility-of-neurofilament-light-chain-in-multiple-sclerosis-a-narrative-review/32098/
[8] MS International Federation. Atlas of MS: Number of people with MS. Accessed 1 April 2026. https://atlasofms.org/map/global/epidemiology/number-of-people-with-ms

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD Phone: +41 79 407 72 58	Lorena Corfas Phone: +41 79 568 24 95
Simon Goldsborough Phone: +44 797 32 72 915	Karsten Kleine Phone: +41 79 461 86 83
Kirti Pandey Phone: +41 79 398 38 53	Yvette Petillon Phone: +41 79 961 92 50
Dr Rebekka Schnell Phone: +41 79 205 27 03	Irène Stephan Phone: +41 79 377 83 75

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Attachment

Roche Media Investor Release CE mark for new Elecsys NfL English

Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply

Mon, 30 Mar 2026 05:00:00 GMT

The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs.
The new test delivers faster turnaround times and allows labs to implement Hepatitis E (HEV) screening without requiring additional instrumentation.
This assay is designed for use on the fully automated cobas x800 systems, enabling high-throughput screening with up to 8 hours of walk-away time.

Basel, 30 March 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the cobas® MPX-E assay, a qualitative in-vitro test for the detection and discrimination of Human Immunodeficiency Virus (HIV 1 and 2) and Hepatitis C, B, and E viruses, is now available in countries accepting the CE mark. This new assay represents a significant advancement in donor screening by consolidating the detection of four major viral targets into a single, efficient workflow. By identifying these pathogens simultaneously, the cobas MPX-E assay helps laboratories streamline their operations while enhancing the safety of blood and blood products for patients.

“Safe, timely access to blood products is a cornerstone of modern healthcare,” said Matt Sause, CEO of Roche Diagnostics. “With the launch of the cobas MPX-E test, we will help ensure that patients receive the safe blood products they need by providing a fully integrated solution that includes the most critical viral pathogens and improves lab efficiency.”

The cobas MPX-E assay is designed to meet the evolving needs of modern laboratories and, through increased sensitivity and specificity, help to prevent HEV transmission through blood transfusions. Hepatitis E (HEV) alone accounts for an estimated 20 million infections and 70,000 deaths annually worldwide.¹ Because many carriers are asymptomatic, robust screening is the only way to manage risks to the blood supply.

Additionally, the new test features dual-target detection for HIV-1 group M, targeting two independent regions of the viral genome to improve sensitivity and ensure reliable results even in the presence of mutations.

Nucleic Acid Testing (NAT) blood screening is approximately 800m CHF globally with an expected Compound Annual Growth Rate of +2% from 2024 to 2029.²

The assay runs on the fully automated cobas® x800 systems (cobas® 6800/8800 and cobas® 5800), which are already used by laboratories worldwide to run more than 10 million tests per month.

About the cobas MPX-E assay
The cobas MPX-E assay is a multiplex real-time PCR test for the simultaneous detection and discrimination of HIV, HCV, HBV, and HEV in distinct channels. It is designed for use on the cobas x800 family of systems, offering a scalable solution that allows multiple tests to be run simultaneously at the same time. The assay offers flexible testing options, allowing laboratories to test for all four targets or select single targets based on their specific screening requirements. The ready-to-load reagents and automation allow for up to eight hours of walk-away time, freeing up laboratory staff for other critical tasks.

For laboratories currently screening for HEV, this assay offers faster turnaround times. For those looking to implement HEV screening, the cobas MPX-E provides a cost-effective solution that does not require additional floor space or instrumentation

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Klöhn M, Schrader JA, Brüggemann Y, Todt D, Steinmann E. Beyond the Usual Suspects: Hepatitis E Virus and Its Implications in Hepatocellular Carcinoma. Cancers (Basel). 2021 Nov 22;13(22):5867. doi: 10.3390/cancers13225867. PMID: 34831021; PMCID: PMC8616277.
[2] FY24 IQVIA Diagnostics market book

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD Phone: +41 79 407 72 58	Nathalie Altermatt Phone: +41 79 771 05 25
Lorena Corfas Phone: +41 79 568 24 95	Simon Goldsborough Phone: +44 797 32 72 915
Karsten Kleine Phone: +41 79 461 86 83	Kirti Pandey Phone: +41 79 398 38 53
Yvette Petillon Phone: +41 79 961 92 50	Dr Rebekka Schnell Phone: +41 79 205 27 03

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Attachment

Media Investor Release cobas MPX-E English

Invitation to Roche’s Virtual AAN Investor Event

Fri, 27 Mar 2026 09:00:00 GMT

We are pleased to invite investors and analysts to participate in our virtual event on Wednesday, 22 April 2026, to highlight the new data from the Phase III FENhance1/2 study evaluating fenebrutinib vs. Aubagio in RMS, which will be presented at the American Academy of Neurology (AAN) forum from 18-22 April 2026.

17:00-18:00 CEST / 16:00-17:00 BST
8:00-9:00 PDT / 11:00-12:00 EDT

Agenda

Introduction
Bruno Eschli, Head of Investor Relations

Fenebrutinib development overview
Alexandra Goodyear, Lifecycle Leader Fenebrutinib

Ph III (FENhance 1/2) fenebrutinib vs. Aubagio in RMS
Jiwon Oh, MD, PhD, FRCPC, Medical Director, Barlo Multiple Sclerosis Program, Associate Professor, Division of Neurology, St. Michael’s Hospital, University of Toronto, Staff Neurologist, St. Michael’s Hospital, Scientist, Keenan Research Centre of the Li Ka Shing Knowledge Institute

Q&A

The slides will be available for download at 16:00 CEST on the day of the event. > click here

Access to virtual event (pre-registration required)

Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli Head of Investor Relations	Loren Kalm Head of Investor Relations, North America
Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Invitation to Roche’s First Quarter Sales 2026 Presentation

Mon, 23 Mar 2026 09:00:00 GMT

Roche will publish its Sales Results for the 1^st Quarter 2026 prior to the opening of the Swiss Stock Exchange on Thursday, 23 April 2026. 07:00 CEST / 06:00 BST / 01:00 AM EDT / 10:00 PM PDT (evening before) Release will be e-mailed and posted on the Roche IR website > click here Presentation slides will be posted on the Roche IR website > click here 14:00 – 15:30 CEST / 13:00 – 14:30 BST 08:00 – 09:30 AM EDT / 05:00 - 06:30 AM PDT The webinar will start with presentations by senior management, followed by a Q&A session. Presenters: Thomas Schinecker, CEO Roche Group Alan Hippe, Chief Financial Officer Teresa Graham, CEO Roche Pharmaceuticals Matt Sause, CEO Roche Diagnostics We would like to invite all interested parties to participate in the webinar and to pre-register for the event here.* Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via > ir.roche.com *privacy notice Best regards,
Bruno Eschli Head of Investor Relations
Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Invitation to Roche’s Diagnostics Day 2026

Mon, 16 Mar 2026 09:00:00 GMT

The Roche Investor Relations team would like to invite you to the Roche Diagnostics Day taking place in London on Tuesday, 12 May 2026, starting at 12:00 BST local time and finishing at 15:45 BST, followed by refreshments with the Roche Management Team.

The Roche Diagnostics Day will address the following topics:

Group and Diagnostics division strategy updates
Launch updates for mass spectrometry, SBX sequencing, and CGM
Foundation Medicine strategy and highlights
Portfolio updates on Core Lab, Molecular Lab, Near Patient Care, and Pathology Lab

Presenters include:

Thomas Schinecker, CEO Roche Group
Matt Sause, CEO Roche Diagnostics
Palani Kumaresan, Global Head of Roche Diagnostics Solutions
Moritz Hartmann, Global Head of Roche Information Solutions
Josh Lauer, Global Head of Customer Area Molecular Labs
Daniel Malarek, CEO Foundation Medicine
Laura Apitz, Head of Pathology Lab Customer Segment
Ildiko Amann-Zalan, Head of Research & Development Roche Diagnostics Solutions
Olivier Gillieron, Lifecycle Leader Cardiometabolic and Neurology

Meeting information:
Date/Time (BST):
Tuesday, 12 May 2026
12:00 – 13:00 Registration and lunch
13:00 – 15:45 Presentations & Q&A
15:45 – 16:15 Refreshments with Roche Management Team

Venue
Pan Pacific London
80 Houndsditch
London EC3A 7AB
> map

To register for the event, please follow this > link (passcode: Dia2026).

The slides will be available for download at 11:30 BST on the day of the event.
> click here

Alternatively you may participate virtually in the webinar (no access to speakers, pre-registration required). Please pre-register for the webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the event will be available via > roche.com/investors

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Birgit Masjost
Investor Relations Officer/Lead Diagnostics

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Last trading day of non-voting equity securities (Genussscheine) and first trading day of participation certificates (Partizipationsscheine) at SIX Swiss Exchange

Mon, 16 Mar 2026 06:00:00 GMT

Roche’s existing non-voting equity securities, Genussscheine under the ticker symbol “ROG”, will have their last trading day on the SIX Swiss Exchange today.
All Genussscheine are 1:1 exchanged for participation certificates, which will commence trading under the new ticker symbol “ROP” on the SIX Swiss Exchange at 9:00 a.m. CET tomorrow, 17 March 2026.
The 1:1 exchange of Genussscheine held as intermediated securities for participation certificates will be processed via the banking system and participation certificates are automatically credited to accounts of such holders.
Participation certificates are economically equivalent to Genussscheine and have the same entitlements to dividends and liquidation proceeds as the bearer shares.

Basel, 16 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its current non-voting equity securities, Genussscheine, will have their last trading day on the SIX Swiss Exchange today, 16 March 2026 (the “cum date” for the exchange). The first trading day of the participation certificates on the SIX Swiss Exchange will be tomorrow, 17 March 2026 (the “ex date” for the exchange). Participation certificates will commence trading on the SIX Swiss Exchange at 9:00 a.m. CET and carry a new International Securities Identification Number (CH1499059983), a new Valor (149.905.998) and a new ticker symbol (“ROP”), which are different from those previously used for Genussscheine.

For holders who hold their Genussscheine as intermediated securities, the transition from Genussscheine to participation certificates does not require any action. Participation certificates will be processed through the banking system and automatically credited to the account of such holders by their custodian bank. Under the T+2 settlement cycle of SIX Swiss Exchange, investors who buy Genussscheine and do not dispose of them on or before 16 March 2026 (the “cum date” for the exchange) and whose purchases have settled so that they are holders of record on the record date for the exchange on 18 March 2026 are expected to receive participation certificates as intermediated securities. Transactions in Genussscheine that remain pending, or orders which remain open, at the end of 16 March 2026 may need to be re-entered as of 17 March 2026 and may not be reflected in holdings as of the record date. For further information, investors should contact their custodian bank.

Holders of printed certificates representing Roche equity securities (“home custodians”) are urged to promptly submit their printed certificates, together with the remaining dividend vouchers (if any), to a depository bank for conversion into intermediated securities. This will ensure smooth future dividend payments to current home custodians and avoid a potential loss of dividend claims. Dividends will be forfeited if not claimed within five years.

For additional details on the exchange of Genussscheine for participation certificates, please refer to the listing prospectus, the information document and consult the dedicated FAQ section available here.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Attachment

260316_IR_Release_last day of trading GS_EN